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A map of 191 single-nucleotide polymorphism (SNPs) was built across
a 5-Mb segment from chromosome 13q34 that has been genetically
linked to schizophrenia. DNA from 213 schizophrenic patients and 241
normal individuals from Canada were genotyped with this marker
set. Two 1,400- and 65-kb regions contained markers associated with
the disease. Two markers from the 65-kb region were also found to
be associated to schizophrenia in a Russian sample. Two overlapping
genes G72 and G30 transcribed in brain were experimentally anno-
tated in this 65-kb region. Transfection experiments point to the
existence of a 153-aa protein coded by the G72 gene. This protein is
rapidly evolving in primates, is localized to endoplasmic reticulum
Golgi in transfected cells, is able to form multimers and specifically
binds to carbohydrates. Yeast two-hybrid experiments with the G72
protein identified the enzyme D-amino acid oxidase (DAAO) as an
interacting partner. DAAO is expressed in human brain where it
oxidizes D-serine, a potent activator of N-methyl-D-aspartate type
glutamate receptor. The interaction between G72 and DAAO was
confirmed in vitro and resulted in activation of DAAO. Four SNP
markers from DAAO were found to be associated with schizophrenia
in the Canadian samples. Logistic regression revealed genetic inter-
action between associated SNPs in vicinity of two genes. The asso-
ciation of both DAAO and a new gene G72 from 13q34 with schizo-
phrenia together with activation of DAAO activity by a G72 protein
product points to the involvement of this N-methyl-D-aspartate
receptor regulation pathway in schizophrenia.
Schizophrenia affects almost 1% of the world’s population,with a similar prevalence throughout diverse ethnic groups
(1). Clinically, this disease, one of the largest causes of disability
worldwide, comprises thought disorder, delusions, hallucina-
tions, and blunted affect, exhibiting extensive individual varia-
tion. Dopaminergic and more recently glutamatergic neuro-
transmission systems abnormalities have both been considered in
schizophrenia pathogenesis (2–6). Molecular mechanisms trig-
gering schizophrenia remain elusive. Although several environ-
mental risk factors have been considered (7, 8), risk studies with
twins and other relatives suggest a highly heritable disease (9).
Identification of schizophrenia genes is particularly challenging,
because the disease may encompass several entities that have not
yet been defined, limiting the accuracy of schizophrenia diag-
nosis as a phenotypic definition. In addition, the lack of con-
clusive linkage from genome scans could be due to the existence
of numerous susceptibility genes having weak individual effects
that are difficult to detect and replicate (10).
In an attempt to track such susceptibility genes, we focused on the
human chromosome 13q22-q34 region that generated linkage
scores in some but not all sets of affected families, ranging from
suggestive to significant in several studies (11–15). The compiled
linkage data pointed to a large 50-cM region that potentially
harbors one or several predisposition genes (Fig. 1a). The distal
5-Mb part of this region around marker D13S174, showing after
analysis of 54 affected families a nonparametric linkage score of
4.18 (13), was investigated by using linkage disequilibrium (LD)-
based positional cloning (16).
Our strategy consisted of systematic single-point association
analysis, replication in another population, haplotype analysis, gene
discovery, and functional studies to provide the convergent lines of
evidence necessary for the dissection of a common multifactorial
disease such as schizophrenia.
Methods
Collections. The French Canadian collection sample consisted of
213 cases and 241 controls recruited throughout the Province of
Quebec. Research protocols, including ethical procedures to be
followed during the study, were submitted to the Institutional
Review Board of each institution. All patients and family members
as well as controls signed consent forms. Patients had to be
diagnosed as schizophrenic by Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV criteria (17). A case was included if it
was not too closely related to other cases (over seven meiotic steps),
and if more than two-thirds of his ancestors could be identified in
any generation up to and including the sixth generation to ensure
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French Canadian origin. Controls were recruited in the same
geographical regions as the cases. Genetic homogeneity between
cases and controls was assessed by using a set of 27 ‘‘random’’
markers from five different chromosomes by using the test derived
by Pritchard and Rosenberg (18). The analysis of allelic frequencies
of these markers shows total 2  23.28, df  27, P value  0.71.
The Russian collection was composed of 183 cases and 183
controls. Cases were recruited from a psychiatric hospital in Mos-
cow [Research Center of Mental Health (RCMH) of the Russian
Academy of Medical Sciences]. The study was approved by the
ethical committee of RCMH. Informed consent was obtained for
all patients and controls. The structured interview (19) was admin-
istrated to each patient, and diagnosis was made in accordance with
International Classification of Disorders 10 and DSM-III-R crite-
ria. The population-based controls were recruited by questionnaire.
Genetic homogeneity between cases and controls was also checked
with a set of 20 ‘‘random’’ markers by using the same statistical test
of Pritchard and Rosenberg applied to the French Canadian
collection. The analysis shows total 2  25.6, df  20,
P value  0.18.
Subcloning and Sequencing the Candidate Region. Fifty-four bacte-
rial artificial chromosome clones were sequenced by using the
random shotgun method. After contigation (3.7 Mb; GenBank
accession nos. AE014293 and AE014294), two gaps remained. To
fill the gaps, sequences were subjected to BLAST (20) analysis against
publicly available databases and the Celera sequence database.
Contigation of all these sequences resulted in a single sequence of
4,995,781 bp. The entire compiled sequence and its annotation are
available on the Genset web site, www.genset.frschizophrenia-
gene-paper. Annotation prediction was performed on this 5-Mb
region by using BLASTN to compare DNA sequences (GenBank,
dbEST) and BLASTX to compare protein sequences (SwissProt,
Sptrembl), GENSCAN (21), and GRAIL2 gene prediction software
with standard parameters. We also used online predictions with the
help of FGENES, GENEMARK, and OTTO software.
The synthenic mouse genomic bacterial artificial chromosome
sequences have GenBank accession no. AY143165.
Single-Nucleotide Polymorphism (SNP) Identification and Genotyping.
SNPs were identified from pools of 100 unrelated French individ-
uals through resequencing 500-bp amplicons covering the 5-Mb
region as previously described. SNP genotyping was performed by
allele-specific ddNTP termination of sequencing reactions. One
hundred ninety-one SNP markers from chromosome 13, 8 markers
from DAAO gene region on 12q24, and 27 whole-genome SNPs
used for stratification homogeneity test were registered in dbSNP
with aliases SS5105638–SS5105863.
Association Analysis. Single-locus tests of association between either
SNP allele frequencies or SNP genotype frequencies and case-
control status were carried out via standard contingency 2 tests,
and P values were determined via 2 tables (22). The null distri-
butions of significant test statistics were validated empirically via
permutation tests. We performed 20,000 permutations for most
significant tests to determine empirical significance. The standard-
ized measure of linkage disequilibrium (LD), termed D, was
computed in each group for alleles at pairs of SNP loci (23). Tests
of departures from LD were performed by using the likelihood ratio
test of linkage disequilibrium as implemented in ARLEQUIN (24).
Haplotype frequencies were estimated via the method of maximum
likelihood from the genotype data through the use of the Expec-
tation–Maximization algorithm under the assumption of the Har-
dy–Weinberg equilibrium (25–28). Logistic regression analyses to
examine genetic interactions were performed by using the com-
mercial SAS package, Ver. 8.1 (29).
Experimental Annotation. Testis and brain ‘‘Marathon Ready’’ cD-
NAs from CLONTECH were used. Rapid amplification of cDNA
ends experiments were carried out as indicated by the manufac-
turer. PCR products were sequenced by using the big dye termi-
nator DNA sequencing reaction (ABI Perkin–Elmer) following the
manufacturer’s instructions. Sequences were assembled by using
the STADEN package and aligned to the genomic sequences to detect
exonintron boundaries. Reverse transcription was carried out by
using the Advantage reverse transcription for PCR kit (CLON-
TECH) according to the manufacturer’s instructions. Full-length
cDNAs were amplified by PCR by using primers in terminal 5 and
3 exons. PCR products were cloned in pGEM11Zf() (Promega)
and sequenced as previously described. cDNA sequences have
GenBank accession nos. AY138546–AY138548.
In Vitro Translation Assay. Coupled in vitro transcriptions
translations of the pGEM-LG72 (G72 candidate gene) and pGEM-
LG30 (G30 candidate gene) plasmids were performed as described
by the manufacturer (TNT quick coupled Transcription
Translation systems, Promega).
Transient Transfection Experiments and Western Blotting. Ten mi-
crograms of pCMV-LG72 () (sense orientation), pCMV-LG72
() (antisense orientation) or pHM6-LG72 (Roche, Molecular
Biochemicals) eukaryotic expression constructs were transfected
into 2.105 COS-7 cells (American Type Culture Collection no.
CRL-1651) according to the calcium phosphate procedure (In-
vitrogen, calcium phosphate transfection kit). One hundred twenty-
five micrograms of each extract were fractionated on a 15%
Fig. 1. Strategy used to identify potential schizophrenia genes in chromosome
13q. (a) Schizophrenia linked region (50 cM) derived from several studies (11–15).
The position of the 5-Mb region selected for association studies is marked. (b)
Allele frequencies association tests performed by Armitage trend test are shown
as –Log (P value) for 191 markers. Thresholds for P values of 5E-02 (straight line)
and 1E-02 (dotted line) are indicated. Statistically significant markers (P value
lower than 5E-02) obtained in this study are shown: 99-13064328 (M-1), 99-
62753178 (M-2), 99-62654305 (M-3), 99-26234336 (M-4), 99-26189164 (M-5)
in Bin B and 99-16105152 (M-12), 99-5919215 (M-22) in Bin A. These last two
markers present P values lower than 1E-02. (c) Location of genes found in the
5-Mbanalyzedregion.Predictedgenesfoundintheproximal2-Mbportionofthe
region are shaded red (1, CanIon; 2, IT6BL1; 3, FHF4; 4, TPP2; 5, PHSP8; 6, XPG; 7,
SLC10A2); unpredicted genes found in the distal 3 Mb described in this study are
shaded blue (8, G90; 9, G72; 10, G30).
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polyacrylamide gel and transferred to nitrocellulose membrane
(Protran BA85, Schleicher & Schuell) at room temperature. An-
tibody staining was performed with the anti-pLG72 purified anti-
serum (SE3014, Eurogentech, Brussels) diluted 1:250. Immuno-
complexes were detected with the enhanced chemiluminescence
Western blotting analysis system (Amersham Pharmacia–
Pharmacia Biotech).
Protein Purification and Enzymatic Activity. The untagged recombi-
nant pLG72 protein was purified from bacteria [E. coli BL21(DE3)
Codon Plus RIL, Stratagene] transformed with the pET11a vector
with the insertion of pLG72 coding sequence. Bacterial cells were
extracted with BugBuster reagent (Novagen) in the presence of
protease inhibitors mixture (setIII, Calbiochem) and 10 mM EGTA
at pH 8. After ammonium sulfate fractionation, proteins were
subjected sequentially to Ultragel AcA44, DEAE-Macroprep (Bio-
Rad), and Superdex 75 (Pharmacia) chromatographies in PBS, pH
8, followed by ultrafiltration (BioMax membrane, 10-K cutoff). Pig
kidney DAAO was purified to homogeneity from Sigma crude
preparation. DAAO was assayed by the colorimetric method (30).
Yeast Two-Hybrid Screening. To identify the physical partners of the
G72 candidate gene product, a portion of it coding for the carboxyl
terminal 89 amino acids was used as a bait in protein interaction
experiments by using the Matchmaker Two-Hybrid System from
CLONTECH (catalogue no. K1612-1). The pretransformed 5106
independent clones of Human Brain Matchmaker cDNA library
(CLONTECH, catalogue no. HY4004AH) was used as prey fol-
lowing experimental procedures recommended by CLONTECH.
The physical interaction between the G72 protein fragment and the
DAAO protein was confirmed by transfer into the opposite mating
type as well as cotransfections of two-hybrid constructs containing
complete G72 fusion and DAAO fragment.
Results and Discussion
The LD association strategy requires a high-density marker map.
The vast majority of human polymorphic sites are single-
nucleotide position variations (SNPs) that are mostly biallelic
(31), with several millions of such potential markers spread over
the genome (32). Because functionally relevant polymorphisms
are expected to be associated with the disease, anonymous
flanking SNPs in strong LD with such functional polymorphisms
are also expected to be disease associated. Our marker map was
constructed dynamically until, using an entire set of 191 markers
in the region, the average LD between consecutive markers had
reached at least 0.85 (0.5 in 70% of the cases), as estimated by
normalized D value. This 191-SNP marker map was built also
in parallel with bacterial artificial chromosome physical mapping
and sequencing followed by integration of available genomic
data from various sources (33, 34). Disease association was
tested by genotyping each marker in 213 unrelated cases and 241
unrelated controls originating from Quebec, which was shown
experimentally to be genetically homogeneous.
Fig. 1b shows the plot of the statistical significance [Log(P
value)] of the allelic association with schizophrenia obtained for
each marker in 13q34. At the nominal significance level of 0.05,
two smaller regions containing associated markers were evident.
We refer them as Bin A, 65.9 kb in length between M-12 and M-22
(Fig. 1b; Table 1), and Bin B, 1,380 kb in length between M-1 and
M-5 (Fig. 1b). These results should be interpreted with caution
because multiple testing implicated 191 markers. At the level of
significance obtained here, a certain number of type one errors
(false positives) are expected to occur. The number of these false
Table 1. Statistical analysis for SNPs in and around Bin A in French Canadian and Russian samples
Twenty markers have been selected in and around Bin A: 99-25965399 (M-6), 99-25966241 (M-7), 99-25989398 (M-8), 99-16047115 (M-9), 99-16052214
(M-10), 99-15875165 (M-11), 99-16105152 (M-12), 99-16032292 (M-13), 99-15880162 (M-14), 99-16038118 (M-15), 8-155258 (M-16), 99-15870400 (M-17),
99-5897143 (M-18), 8-130143 (M-19), 99-24644194 (M-20), 99-24658410 (M-21), 99-5919215 (M-22), 99-5862167 (M-23), 99-24634108 (M-24), and
99-31941320 (M-25). The distance between M-6 and M-25 is 265.7 kb. This table shows data for markers and results from univariate analysis. PositionGene line
indicates the relative position of G72 (red) and G30 (blue) in reference to SNPs. The type of polymorphism is indicated, and the allele with increased frequency
in French Canadian cases compared to French Canadian controls is underlined. Significant P values (lower than 5E-02) are lighted in red. [, P values higher than
1E-01; HW Da, Hardy–Weinberg disequilibrium; ns, not significant HW Da (exact P value higher than 5E-02); nd, not done.]
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positives can be diminished by performing correction of nominal
values, taking into account the number of independent tests per-
formed (Bonferroni correction) (35), or by performing a multiple
permutation test. Although effectively controlling the frequency of
type one errors (false positives), this type of correction can increase
the probability of type II errors (false negatives) to an unacceptably
high level. Moreover, the 191 tests were not independent. It is also
important to note that, whereas associated markers caused by type
one errors should be distributed randomly throughout the region,
substantial clustering of independent associated markers is ob-
served in our case. This is especially evident in the case of Bin A,
where clustering is probably meaningful because more than two
independent markers (not in a strong LD; Fig. 5, which is published
as supporting information on the PNAS web site, www.pnas.org)
exceed the nominal 1% level, and they are relatively close. Using
haplotypes instead of individual markers for association could
reduce the chance of false-positive findings by providing stronger
statistical support for the region. We calculated the estimated
frequencies of all 9,000 possible combinations of three-marker
haplotypes for 20 SNP markers in and around Bin A (Table 1)
separately for cases and controls. The vast majority of these
haplotypes are not independent, because a strong LD exists in this
bin (Fig. 6, which is published as supporting information on the
PNAS web site). To reduce the number of haplotypes for further
examination, we retained only haplotypes that are ‘‘common,’’ i.e.,
with allelic frequencies in controls of at least 4%, and provide
stronger statistics than single markers (odds ratio of more than 1.5
with P values of 0.001). Thirty-seven resulting three-marker
haplotypes meet these criteria (Table 2, which is published as
supporting information on the PNAS web site, www.pnas.org). The
strongest nominal value we observed was 3.551010. The null
distributions of significant test statistics were approximated by
performing 20,000 permutation tests. Some of these common
haplotypes still show P values close to zero despite such correction.
For two of them (Table 2, first and third lines), we performed
further correction through 50,000,000 permutations and produced
strong P values of 3106 and 5105.
For replication, we genotyped, with a subset of 13 markers linked
to Bin A, 183 schizophrenic cases and 183 controls from Moscow.
The results are shown on Table 1. Marker M-23 gave a genotypic
association with a P value of 0.0004 and a weaker allelic association
with a P value of 0.017, comparable to what was observed in the
larger French Canadian sample. Marker M-24, which gave signif-
icant univariate P values in the Canadian sample, is in LD (D 
0.99) with marker M-23. It also gives a P value of 0.006 for genotypic
association in the Russian collection.
Gene Discovery in the 13q Subregion. Computational gene annota-
tion, performed across the entire 5-Mb region, showed the presence
of several potential genes. Annotation of some of these genes was
then completed experimentally by reverse transcription–PCR and
rapid amplification of cDNA ends. As a result, seven genes were
assigned to the proximal 2-Mb portion of the region (Fig. 1c).
The distal 3 Mb could be referred as a ‘‘gene desert’’ (34), with
only sparsely located expressed sequence tags. Both Bins A and B
mapped within this ‘‘gene desert.’’ Nevertheless, we decided to
perform an experimental annotation within and around Bins A and
B. By this process, several potential genes were identified within the
putative gene desert (Fig. 1c). Within Bin B, a large gene containing
at least 20 exons spanning 591 kb was found. The experimental
annotation of this gene, named G90, is still being undertaken. A
250-kb segment centered on 65-kb Bin A was extensively screened
by experimental annotation. This segment harbors two genes
named G72 and G30, both entirely located within associated Bin A.
They are transcribed from the two opposite DNA strands and span,
respectively, 29 and 47 kb. G72 is entirely included in G30 (Fig. 6).
Interestingly, exons of these three genes cannot be predicted by any
tested computational method. On the basis of reverse transcrip-
tion–PCR full length transcript cloning and sequencing, both G72
and G30 generate numerous splice variants in various parts of
human brain, spinal cord, and testis. The longest possible G72 ORF,
named LG72, is coded by transcripts detected in amygdala, caudate
nucleus, spinal cord, and testis. It encodes a 153-aa protein referred
to as pLG72 (Fig. 2). Other G72 splice variants share a short
common ORF encoding a 16-aa peptide and were detected in testis,
different parts of brain, and spinal cord. The longest potential G30
ORF, named LG30, encodes a 71-aa-long putative protein referred
to as pLG30. LG30-containing transcripts were detected in several
brain regions. No statistically significant homology (E value0.05)
could be found between these G72 and G30 potential proteins and
any confirmed or hypothetical protein. We isolated and sequenced
a syntenic mouse bacterial artificial chromosome from mouse
chromosome band 8A. It contains eight highly conserved blocks
collinear in mouse and human genomes. None of these blocks (Fig.
6) overlap with potentially coding parts of G72 or G30. They do not
code for human or mouse larger ORFs. No new human or mouse
transcripts were detected when these blocks were used as entry
points for experimental annotation. By using extended PCR prim-
ers, we were able to amplify and sequence coding exons and
flanking genomic DNA of LG72 in rhesus monkey and ape
genomes. The alignment of corresponding hypothetical pLG72
protein is shown in Fig. 7. In rhesus monkey, most of the exons
contain stop codons, and the vast majority of splice sites are
mutated. Potential pLG72 orthologues can be deduced for chim-
panzee, gorilla, and gibbon genomes. The chimpanzee ORF length
is almost half the length of the human LG72 ORF. This is surprising,
because only 1% of nucleotide changes occur between chimpanzee
and human (36), with most proteins nearly identical in both species.
Therefore, G72 could represent a rare case (37) of a primate-
specific gene with a rapidly changing protein structure presumably
connected with a rapid evolution of underlying brain function.
Because G72 and G30 reside entirely within the 65-kb-long Bin
A and are covered by statistically significant haplotypes, they
represent potential disease candidates.
Functional Analysis of Putative Protein Product. As a first step for
functional analysis of G72 and G30 candidate genes, we performed
coupled in vitro transcriptiontranslation for each of them (Fig. 3a).
Only LG72 gave a specific 24-kDa translation product. No product
Fig. 2. Structure of LG72 protein and evolution of its putative orthologues in
primates. DNA from four different primates (chimpanzee, gorilla, gibbon, and
rhesus monkey) were amplified by using specific primers from the human G72
gene. Amplicons were sequenced, and exons were defined by homology to the
corresponding human exons. Alignment of theoretical polypeptide sequences
corresponding to pLG72 in human and these different primate species is shown.
pLG72 translation in chimpanzee and gorilla is altered by a 4-nt insertion causing
aframeshiftandapremature stop. In rhesusmonkey, the insertionofoneTat the
end of Exon M causes a frameshift and a premature stop.
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was detected for LG30, whose translation might require tissue-
specific factors. Alternatively, the function of transcripts of this gene
could reside in regulation of G72 expression by an antisense
mechanism.
Because of the lack of experimental evidence for a G30 protein,
we proceeded further solely with LG72. Rabbit antibodies were
raised against bacterially produced 6HIS-tagged pLG72 and were
purified on immobilized recombinant pLG72 tagged by glutathione
S-transferase. The purified antiserum was used for Western blot
analysis of proteins produced by COS7 cells transiently transfected
by a nontagged LG72-containing construct (Fig. 3b). Twenty-four-
and 13.5-kDa specific products were clearly detected. However, the
theoretical molecular mass of the 153-aa-long pLG72 is 18, not 24,
kDa. We consistently observed this 6-kDa difference in apparent
molecular mass for both tagged and nontagged pLG72 produced by
in vitro translation, in bacteria, yeast, or eukaryotic cells. This might
be due to a particular secondary structure persisting even after
denaturation in reducing conditions. The 13.5-kDa product may
result from a proteolytic cleavage from the full length protein.
Characterization of the properties of a protein coded by a given
ORF may help to elucidate its function and to distinguish genuine
proteins from possible artifacts. We found that in transiently
transfected cells, this protein is localized specifically to Golgi (Fig.
7, which is published as supporting information on the PNAS web
site). Bacterially produced pLG72 protein, in addition to the
previously mentioned abnormal migration in SDS-containing gels,
shows the ability to form dimers and oligomers and binds specifi-
cally to -D-galactopyranoside residues (Fig. 8, which is published
as supporting information on the PNAS web site), placing it
functionally among galectin-like proteins.
Preliminary Mutation Search in 13q Gene G72. Among 20 markers in
and around associated Bin A, two common SNPs could have
potential consequences for gene function. Marker M-15 (99–
16038118) is the only common SNP in the region that could
influence directly the structure of LG72 protein (lysinearginine
polymorphism at position 29 of ORF). Despite the conservative
nature of an arginine-to-lysine substitution, numerous examples of
drastic functional changes are known for different classes of pro-
teins (38, 39). This marker gives an allelic P value of association of
0.03 and is in high LD (P value of105) with the mostly associated
marker M-12. Six of 37 haplotypes presented in Table 2 contain
marker M-15. Another potentially functional common SNP is
marker M-19, situated 15 bp upstream of the 5 end of protein-
coding exon Qbis, the part of consensus for an acceptor splicing site.
Although M-19 does not show association by itself, it is present in
two haplotypes of Table 2. This polymorphism is changing one
pyrimidine (C) for another (T) in a polypyrimidine-containing part
of this consensus. We do not know for the moment what could be
the consequences of such a change to the splicing of the G72
transcript. Although the nucleic acid polymorphisms of M-15 and
M-19 could have some functional effect, it is clear that they cannot
explain entirely the complex pattern of association in Bin A. Several
haplotypes are giving lower P values than single markers, which
could mean that as-yet-undiscovered disease-specific sequence
variations are contained in strongly associated haplotypes. An
alternative explanation may be that these common haplotypes are
themselves functionally relevant, predisposing to the disease be-
cause of the synergistic effect of their constituent SNPs, as was
recently described (40).
Analysis of G72 Functional Interactions. To investigate whether
pLG72 could influence a pathway implicated in schizophrenia, we
attempted to identify potential interacting proteins from human
brain. With this aim, we screened 500,000 independent clones from
a human brain cDNA library in a two-hybrid yeast system (41).
Screening the library, we found a nearly full length clone (300
amino acids of 347) of D-amino acid oxidase (DAAO). DAAO is
able to oxidize D-serine, an allosteric activator of the NMDA-type
glutamate receptor (42). NMDA receptors are ligand-gated ion
channels, which have a modulatory site for the amino acids glycine,
and D-serine (43). The modulatory site must be occupied by these
ligands for glutamate to stimulate cation flow.
A physical interaction between pLG72 and DAAO was con-
firmed in vitro by column binding and glutathione S-transferase pull
down (Fig. 9, which is published as supporting information on the
PNAS web site). To evaluate the impact of this physical interaction
on DAAO activity, we measured D-serine oxidation by DAAO in
the presence of increasing concentrations of recombinant pLG72.
Data shown in Fig. 4 suggest that pLG72 behaves as an activator of
DAAO. This activation approaches its maximum value at pLG72
DAAO molar ratios of 5:1 calculated for the monomer form of
these proteins. These in vitro results could suggest the participation
of pLG72 in the regulation of NMDA-type glutamate receptors in
specific parts of the human brain. If some individuals were to
overproduce pLG72, they could exhibit a lower NMDA-type glu-
Fig. 3. In vitro and ex vivo translation of the G72 candidate gene. (a) Coupled
invitro transcriptiontranslationassays in thepresenceof [35S]-Met forbothLG72
(lane 1) and LG30 (lane 2) cDNAs, unprimed lysates (lane 3), and a luciferase cDNA
control (lane 4). (b) Expression vectors harboring the nontagged LG72 cDNA
either in theantisenseorientation () (lane2)or in thesenseorientation () (lane
3) were transfected into COS-7 cells and the expressed proteins analyzed with a
purified anti-pLG72 serum. A His-Xpress-pLG72 recombinant protein (5 ng) pu-
rified from bacteria was run as a control (time exposure for this lane is shorter
than for the two others). The His-Xpress tag is 33 amino acids long.
Fig. 4. Oxidation of D-serine by DAAO in the presence of LG72 protein. Activity
is expressed as amount H2O2 generated as a result of oxidation of D-serine. The
concentration of DAAO was constant (45 ngl), the concentrations of pLG72
varied from 0 to 680 ngl, and BSA was added to maintain the equal total
protein concentration. The curves represent the mean of the three measures for
each incubation point. Confidence interval (‘‘error bars’’)  mean (three mea-
sures) plus or less 1.96. *, Standard deviation (three measures).
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tamate receptor activity predisposing them to schizophrenia, which
could result in glutamate signaling hypofunction, a mechanism
recently proposed in schizophrenia (44–48).
Association Studies of DAAO and Its Genetic Interaction with Chro-
mosome 13q Markers. We attempted to verify genetically the hy-
pothesis that G72 and DAAO operate in the same pathological
pathway. We developed eight common SNPs, separated on average
by 17 kb, covering the DAAO gene on human chromosome 12q24.
They were then tested for disease association in the same French
Canadian casecontrol samples that led to the identification of G72.
Four intronic SNPs, in partial linkage disequilibrium (MDAAO-4,
MDAAO-5, MDAAO-6, and MDAAO-7) gave significant associ-
ation P values by univariate analysis as shown in Table 3, which is
published as supporting information on the PNAS web site.
Finally, we tried to investigate whether the functional molecular
interaction of pLG72 and DAAO detected in vitro can be confirmed
through statistical analysis for interaction between these two genes.
In principle, the concept of interaction is straightforward: the
combined effect of two risk factors in increasing the risk for the
disorder is higher than the effect of each single factor per se. In our
case, the definition of the phenotype is qualitative, being either
present or absent, and the synergic effect of the two genes can be
measured by estimating the odds ratios (OR) for the combinations
of genotypes at different polymorphisms in G72 and DAAO (49).
We therefore examined the joint effect of M-22 and MDAAO-6,
the markers showing the greatest evidence for association with
schizophrenia at G72 and DAAO, by considering the genotypes at
risk for both polymorphisms (Table 4, which is published as
supporting information on the PNAS web site). The synergistic
effect is calculated as genotypegenotype interaction in a logistic
regression model: there are four possible genotypes at risk for M-22
and MDAAO-6, e.g., M-22AA, M-22AG, MDAAO-6GT, and
MDAAO-6TT, leading to four possible meaningful interaction
factors among those genotypes. The genotype M-22AA
MDAAO-6TT shows a significant interaction effect with an
estimated OR of 5.02, P value of 0.04, which is greater than the
‘‘additive’’ effect of M-22AA (OR  1.89) and MDAAO-6TT
(OR 1.04), consistent with a multiplicativeepistatic effect of the
two polymorphisms jointly considered (Table 4).
Together, these various results provide convergent evidence for
the interpretation that G72 and DAAO may both contribute risk
for schizophrenia via the same pathological pathway, at least in
some individuals. Future genetic and functional work is necessary
to further validate these data converging toward the contribution of
G72 and DAAO in schizophrenia and to exclude other possible
genes in LD with them. First, the association results should be
confirmed by independent groups in other populations. Association
with Bin A markers was recently replicated in a familial trio sample
by TDT analysis (D.W., unpublished results). Large-scale human
brain mRNA and protein differential expression as well as D-serine
local concentration measurements will provide important elements
for such validation and will elucidate the relationship of genotype
to expression profile. Because the NMDA receptor is critical for the
development and modifiability of neuronal contacts, the specific
expression of G72 and DAAO during both prenatal and postnatal
development should also be addressed. At present, little is known
about genes predisposing to schizophrenia and their interaction
with environmental factors. The application of an LD-based asso-
ciation strategy may be less efficient if several susceptibility alleles
for each gene exist. Moreover, the susceptibility to schizophrenia
could be highly epistatic, with genes regulating each other in
complex interconnected networks of interactions. The definition of
disease itself is not homogeneous, and the number of predisposing
genes is unknown but likely to be considerable. All these factors will
result in relatively weak statistical values for individual SNP asso-
ciation based on LD. Identification of a subset of patients with
modified expression of G72 or DAAO or with lower D-serine
concentration could produce new molecular markers and may be a
valid step toward etiological stratification of schizophrenia. The
discovery of other predisposition genes and environmental factors
acting on the same pathway may result from studies on this subset
of patients.
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